Information For Authors
- Manuscript Submission Guidelines
- Author Benefits Program
- Open Access Policy
- NIH/HHMI Wellcome Trust Policies
- Self-Archiving Policy
Instructions for Authors
The Journal of Child and Adolescent Psychopharmacology is published 10 times a year. It focuses on Child and Adolescent Psychopharmacology and those aspects of Child and Adolescent Psychiatry, Neurology, Pediatrics, and the neurosciences that are clearly related to this. The Journal publishes papers encompassing investigative research, treatment techniques, basic sciences, health policy and education, focused reviews and clinical case reports or conferences.
Manuscripts must be submitted online using the following url: http://mc.manuscriptcentral.com/jcap. Please read all the instructions to authors before submitting.
Copyright Agreement Form
Manuscripts should be submitted with the understanding that they have neither been published, nor are under consideration for publication elsewhere, except in the form of an abstract. Prior abstract publications should be described in the form of a footnote to the title. Published manuscripts become the sole property of the Journal and will be copyrighted by Mary Ann Liebert, Inc. By submitting a manuscript to the Journal, the author(s) agree(s) to each of the above conditions. In addition, the author(s) explicitly assign(s) any copyrighted ownership he/she (they) may have in such manuscript to the Journal.
Upon acceptance of any manuscript, all authors will receive a follow-up email with instructions on how to complete our online Copyright Agreement form. It is critical to ensure the accuracy of ALL authors’ email addresses when uploading submissions to Manuscript Central to ensure the proper delivery of all email communications.
FAILURE BY ALL AUTHORS TO SUBMIT THIS FORM MAY RESULT IN A DELAY OF PUBLICATION.
The corresponding author is responsible for communicating with coauthors to make sure they have completed the online copyright form. Authors not permitted to release copyright must still return the form acknowledging the statement of the reason for not releasing the copyright.
Deviations from these Instructions for Authors will generally result in a return of the manuscript for correction before review.
The Journal will consider original research papers, brief reports, reviews, and letters to the editors.
Original research articles and brief reports should have an Abstract, Introduction, Methods, Results, Discussion, Conclusions, Clinical Significance, Disclosures, Acknowledgments, if needed, References, Tables and Figures, and Legends. One subsection level is allowed.
Brief reports should be no more than 10 manuscript pages including references and disclosures, and no more than 2 tables (or figures). Case reports of 5 or more cases can be submitted as a brief report.
Case reports of 1-4 cases must be submitted as a Letter to the Editor.
Letters to the Editor(s) are welcomed, but with a 500-word limit and no more than one (1) table OR figure, and with a maximum of four (4) references.
MANUSCRIPT SUBMISSION AND REVIEW
A submitted paper (or any essential part) must not be published or simultaneously submitted to other publications prior to its appearance in this Journal (except for abstracts or press reports from scientific meetings).
Submissions to the Journal will undergo peer review. Manuscripts may be edited for clarity, conciseness, grammar, and conformity to Journal style. Authors will receive page proofs before publication.
Authors should include a minimum of 3 to 5 preferred reviewers (with email addresses) whom they think are particularly expert in the subject of their paper. This information should be provided in the preferred reviewer section during the online submission process through manuscript central.
Accepted manuscripts become the permanent property of the Journal, and may be republished elsewhere only with the written permission of the publisher. There are no page charges.
PREPARATION OF MANUSCRIPTS
All text files should be submitted in Word files. Do not submit PDFs.
All authors must disclose all institutional or corporate/commercial relationships going back 36 months, or to the time of the data collection if the data were collected longer than 3 years ago, that might pose a conflict of interest. The Journal should also be informed if any conflicts of interest arise after submission and before publication of the paper. Institutional affiliations and funding sources that supported the work (from any grant, funding source, or commercial interest/pharmaceutical company) are to be indicated on the title page.
The Author Disclosure section is to be uploaded along with your manuscript as a separate Word file. The disclosure is required for submission. If the authors have nothing to disclose, state this in the file for each author.
The Disclosures should include all corporate/commercial relationships that might pose a conflict of interest, e.g., all of the authors' relationshps with all pharmaceutical companies. This includes such things as all consultancies, honoraria, stock ownership, gifts, free or reimbursed travel/ vacations, equity interests, arrangements regarding patents or other vested interests, etc. (not just those immediately related to this specific paper or to the pharmaceutical company sponsoring the submitted paper). If a specific author has no financial relationships with any pharmaceutical company, it must be so stated in the Disclosure section. If the study was supported by a pharmaceutical company, it must be stated in the Disclosure section who analyzed the data and who wrote the paper (the authors or a medical writer). Papers submitted without an Author Disclosure section will not be reviewed.
On the first page, give the full title of the article, full name(s) and highest academic degree(s) of all author(s), the name of the department and institution where the work was done, and other institutional affiliation(s) and title(s). State the names and affiliations of statistical consultants. Support received from any grant, funding source, or commercial in-terest should be indicated. Also, give name, address, telephone, and email address of the corresponding author and of the author who will receive requests for reprints. Provide a running title that is less than 45 characters. Include an abstract. Please number all pages consecutively.
Whenever possible, the titles of papers should provide specific information rather than merely suggest a general topic. Many readers who scan the medical literature in indexing sources see only the titles, and should receive information by scanning. Titles in the Journal should be self-explanatory and self-contained. Rather than a title such as "Conduct Disorder and ADHD," use "Conduct Disorder Is Present in 70% of Children with Attention-Deficit/Hyperactivity Disorder." Please avoid two-part titles and abbreviations.
All submissions, except letters, must be accompanied by a structured abstract of less than 300 words. The abstract must have the following four sections: Objectives, Methods, Results, and Conclusion. The abstract should be fully understood on its own, without any reference to the text itself. Statements that give generalized accounts, such as "Implications will be discussed," are not helpful: Indicate concisely what are seen as the most important implications.
Tables, Figures, and Illustrations
- Prepare each figure as individual .TIFF or .EPS file
- Do NOT embed figures and/or images within the manuscript file.
- Do NOT submit figures in Word, PowerPoint, PDF, Bitmap, .JPEG, or Excel.
- Line illustrations must be submitted at 900 DPI.
- Halftones and color should be submitted at a minimum of 300 dpi.
- Color art must be saved as CMYK - not RGB. (N.B., If RGB files are submitted, the files will be converted to CYMK and some color variation will occur.)
- Black and white art must be submitted as grayscale – not RGB
- For direction on conerting a Power Point slide to acceptable format go to: www.liebertpub.com/MEDIA/pdf/ppconvert.pdf
- Prepare and save each table in individual .doc or .docx files.
- Do not include tables in the main manuscript text file.
- Do not embed tables within the text.
- Include a table number and a title for each supplied table.
- Use Arabic numerals to number tables.
- Do not repeat information that is given in the text, and do not make a table for data that can be given in the text in one or two sentences.
- Define all acronyms used within the body of the table in table footnotes.
- All other types of table footnotes should be designated using superscript letters, not symbols.
- Name all table files in English and use only alphanumeric characters. Do not use symbols, dots, lines, or dashes.
- Table file names should be formatted with first author’s last name and the figure number. (Ex: SmithTable1)
- Upload individual table file under the “Table” file designation.
When appropriate, we encourage the judicious use of online-only supplementary information (SI). All information/data in the SI should be referred to in the article text, including reference to specific tables and figures in the SI. Upload supplementary tables, figures, and legends as separate files, either as “supplementary file” or “supplementary file for review only.” The manuscript should be written so that the paper which appears in the printed journal contains all data which are key to the conclusions and important for the reader to have direct access to when reading the paper. Other supporting data and text are appropriate for the supplementary section.
In research involving statistical analysis, please include the following: (a) the hypotheses in clearly stated form, (b) the statistical tests used, cited by name, for each data set, (c) the use of either one-tailed or two-tailed tests, and (d) the test value, degree(s) of freedom, and probability for every significant and important nonsignificant result. Use standard deviations rather than standard errors of the mean. For novel or not well-known tests, provide a citation.
Each original research article, review, or brief report should include a "Clinical Significance," just before the Author Disclosure statement. This section requires one brief paragraph that will communicate the clinical importance of the work, and its relevancy to the scientific community, in a few short sentences.
Authors maintain responsibility for the accuracy of their citations. Text citations will appear preferably at the end of sentences, and will indicate first (A 1990), first and second (A and B 1990), or first plus (A plus all coauthors 1990) authors, with year of publication and without a comma. Citations in the reference section should list all coauthors (et al. is not permitted in the reference list), be alphabetized rather than numbered, and multiple citations to one author should be placed in chronological sequence; the list should be double spaced, with each reference separated by a single line of space. Any references published in a foreign language should be followed by an English translation in brackets. Do not indicate issue numbers unless issues are not sequentially paginated. Credit for figures and illustrations should be given in captions. Personal communications, unpublished data, and manuscripts "in preparation" or "submitted for publication" may be incorporated into the text but not in the reference list. Abbreviations will follow the style of Medline. Please follow the style of these examples:
Riddle MA, Hardin MT, King R, Scahill L, Woolston
JL: Fluoxetine treatment of children and adolescents with Tourette's and obsessive compulsive disorders: Preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 29:45-48, 1990.
Courchesne E, Yeung-Courchesne R: Event-related brain potentials. In: Assessment and Diagnosis in Child Psy-chopathology. Edited by Rutter M, Tuma AH, Lann IS. New York, Guilford Press, 1988, pp 264-299.
Adams GR, Montemayor R, Gullotta TP (eds): Biology of Adolescent Behavior and Development. Newbury Park (California), Sage Publications, 1989.
Geller B: A double-blind placebo-controlled study of nortriptyline in adolescents with major depression. Washington (DC), National Institute of Mental Health, New Clinical Drug Evaluation Unit (NCDEU) Annual Meeting, 1989 (abstract).
Abbreviations and Medication Names
Weights, heights, and other measurements should be in the metric system. When an abbreviation or acronym is first used in the abstract and in the text, it must be spelled out in full and followed by the abbreviation in parentheses. When an abbreviation or acronym is used in each table and figure, it should be spelled out in full in the table footnote or figure citation. For standard abbreviations, consult the Style Manual for Biologic Journals, 4th edition (American Institute of Biological Sciences, 1401 Wilson Blvd, Arlington, VA 22209).
Identify medications by generic name. A brand name may also be placed in parentheses; but since brand names are generally used only in a single country, specify the locale in which the proprietary name is used. Proprietary names, but not generic or chemical names, should have initial capital letters. For materials and devices, describe by nonproprietary name, and then indicate (in parentheses) brand name, manufacturer's name, city, state, and country. Be certain to use the brand names of medications or products that are experimental or that are crucial to the replication or interpretation of the study.
Materials taken from other sources must be accompanied by written statements from both author and publisher giving permission for reproduction to the Journal. If clearance is also required by the author's institution, these statements should be provided with the manuscript. For papers in press, unpublished data, and personal communications, submit written permission from the first author along with the manuscript.
Strict anonymity of patients must be maintained. Do not use actual names, initials, dates, or hospital numbers. In describing the personal characteristics of a patient, disguise any potentially identifying information. [The only exception is a photograph of an identifiable patient, for whom written permission for publication has been obtained.]
Informed Consent and Assent
For clinical reports, an explicit description of the informed consent procedures involving both parents, as well as the assent provided by younger adolescents and children, is required in the Methods section. Agreement is required both for consent to research and permission to publish.
Human or Animal Experimentation
Reports of research involving experimental subjects should be accompanied by a statement indicating approval by the Institutional Review Board (or Institutional Animal Care and Use Committee).
Thanking individuals involved in the scientific or technical aspects of manuscript preparation should not exceed four typed lines.
Reprints may be ordered by following the special instructions that will accompany page proofs, and should be ordered at the time the corresponding author returns the corrected page proofs to the Publisher. Reprints ordered after an issue is printed will be charged at a substantially higher rate.
The originality and accuracy of data, statements, and opinions in the Journal are the responsibility and liability of the individual contributors (and advertisers). These statements do not necessarily represent the views of the editors, the publisher, or the Journal.
The Journal is published by Mary Ann Liebert, Inc., 140 Huguenot Street, 3rd Floor, New Rochelle, NY 10801-5215. Telephone: (914) 740-2100; fax: (914) 740-2101; e-mail: firstname.lastname@example.org internet: www.liebertpub.com
Ensure maximum visibility, discoverability, and impact for your article with our Liebert Open Access (OA) option
Does your research funder have an open access mandate or would you like to expand the dissemination of your research?
The Liebert Open Access option enables authors to publish open access in our esteemed subscription-based journals.
The benefits of Liebert Open Access include:
- High visibility; open access articles are freely available online upon publication
- You retain copyright with the open access license allowing broad dissemination of your research
- You can freely share your article in repositories and research networks without restrictions
- Easy compliance with open access mandates
- Rigorous editorial and peer-review
- Targeted email announcement featuring a direct link to article
Identification and Marketing
Open access articles are listed with an OA icon in journal tables of content (TOC), TOC alerts, and in marketing announcements. Open access articles are highlighted and promoted in targeted email announcements to thousands of research leaders in your field.
Copyright and Licensing
If you choose to publish with open access, you will retain copyright of your article and a Creative Commons license will be applied. The liberal Creative Commons Attribution 4.0 (CC-BY) license is the default open access license used at Mary Ann Liebert, Inc., publishers. The CC-BY license permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
Ordering Open Access
Once your article has been accepted for publication in a journal, you will receive an email with information on ordering Liebert Open Access. If you would like more information about Liebert Open Access or would like to order open access, please email email@example.com.
Publishing open access includes an article publication charge (APC) and authors are asked to fill out a short open access order form. You can pay by credit card or receive an invoice to be returned with payment or via bank transfer. Please remember that traditional subscription journals can carry mandatory or optional author fees. The Liebert Open Access APC does not cover or replace existing publication or author fees.
Publishing biomedical or biotechnology research?
Biomedical researchers should consider publishing in BioResearch Open Access, a fully open access peer-reviewed journal dedicated to publishing top research in the biomedical and biotechnology fields. For details, please visit the information for authors on the journal website.
*Please note that PubMedCentral, not the Publisher, has sole control over when the paper is made live on PMC.
Browse journals in the Liebert Open Access portfolio:
NIH Public Access Policy: In order to assist our authors who have NIH funding to comply with this policy, Mary Ann Liebert, Inc. publishers will deposit the final accepted paper (after copy-editing and proofreading) to PubMed Central (PMC) on behalf of the authors. Authors need not take any action. The manuscript's public access posting on PMC will occur 12 months after final publication. This service is provided free of charge. Please note that authors may not deposit manuscripts directly to PMC or other sites without permission from Mary Ann Liebert, Inc.
Publishing in Subscription Journals
By signing the copyright transfer statement, authors still retain a set of rights that allow for self-archiving.
Authors may archive their preprint manuscripts (version prior to peer review) at any time without restrictions. Authors may archive their postprint manuscripts (accepted version after peer review) in institutional repositories, preprint servers, and research networks after a 12 month embargo. The 12 month embargo period begins when the article is published online. Postprints must not be used for commercial purposes and acknowledgement must be given to the final publication, and publisher, by inserting the DOI number of the article in the following sentence: “Final publication is available from Mary Ann Liebert, Inc., publishers http://dx.doi.org/[insert DOI]”. Authors may archive on their personal website without an embargo provided their manuscript is updated with an acknowledgement to the publisher copyright and final published version.
The final published article (version of record) can never be archived in a repository, preprint server, or research network.
Publishing Open Access
Authors that wish to easily comply with funder or institutional open access mandates should consider publishing open access. Liebert Open Access option allows authors to make their research freely available online without restrictions. Additionally, Liebert Open Access option allows authors to retain copyright, archive and share the final published version of their article without restrictions. To publish open access please email firstname.lastname@example.org or visit Liebert Open Access for more information.